|
| Press Releases |
|
 |
|
| Monday, July 13, 2020 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded |
| Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease |
| Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease. more info >> |
|
|
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA. more info >> |
|
| Wednesday, July 8, 2020 |
|
|
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong |
| Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health. more info >> |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide (generic name, development code: E7438, "tazemetostat") for EZH2 gene mutation-positive follicular lymphoma. more info >> |
|
| Monday, July 6, 2020 |
|
|
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan |
| Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020. more info >> |
|
|
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan |
| Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020. more info >> |
|
| Wednesday, July 1, 2020 |
|
|
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID |
| The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai announced today that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. more info >> |
|
| Thursday, June 25, 2020 |
|
|
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea |
| Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide"). more info >> |
|
| Wednesday, June 10, 2020 |
|
|
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa |
| Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel coronavirus infection in Africa, beginning with the activities described below. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Cornerstone Robotics Completes the World's First Clinical Validation of Autonomous Surgery Performed by Robot-Assisted Surgery 
Aug 6, 2025 19:21 HKT/SGT
|
|
|
Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept
Aug 6, 2025 19:40 JST
|
|
|
Phoenitron's E-commerce Business records unaudited aggregated profit before taxation of approximately HK$55.6 million in 1H2025
Aug 6, 2025 18:09 HKT/SGT
|
|
|
Dream Incubator and DENSO Launch Demonstration Project for Digital Platform Development for Mobility Circular Economy and Integrated Manufacturing for India
Aug 6, 2025 18:54 JST
|
|
|
International Land Alliance Brings Baja to Buyers with Live Zoom Webinar Experience
Aug 6, 2025 17:32 HKT/SGT
|
|
|
Luxren Capital Rolls Out High-Performance Mobile Trading App for Global Users
Aug 6, 2025 17:00 HKT/SGT
|
|
|
MyFintech Week 2025 Highlights Transformative Forces in Finance
Aug 6, 2025 17:00 HKT/SGT
|
|
|
HKTDC appoints Sophia CHONG as Executive Director
Aug 6, 2025 16:56 HKT/SGT
|
|
|
Robot Boom in HK: Shoucheng Holdings at the Forefront
Aug 6, 2025 16:35 HKT/SGT
|
|
|
iFex Capital Launches Major Mobile Trading App Overhaul to Meet Surging Demand
Aug 6, 2025 16:00 HKT/SGT
|
|
|
35th Food Expo opens next week five theme days kick off premium lifestyle journey
Aug 6, 2025 15:05 HKT/SGT
|
|
|
AITO launches EV Road Tour from Chongqing to Jakarta
Aug 6, 2025 14:22 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million
Aug 6, 2025 13:20 HKT/SGT
|
|
|
University of Cyberjaya Welcomes Education Reforms under RMK13: A Bold Step Toward Future-Ready Talent and Inclusive Innovation
Aug 6, 2025 12:27 HKT/SGT
|
|
|
Fujitsu's CHRO Roundtable Report 2025 highlights data-driven HRBP practices for human capital management
Aug 6, 2025 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
